Clinical Trials Logo

Liver Neoplasms clinical trials

View clinical trials related to Liver Neoplasms.

Filter by:

NCT ID: NCT05383066 Not yet recruiting - Clinical trials for Carcinoma, Hepatocellular

Anti-angiogenesis Combined With PD-1/PD-L1 Therapy in Patients With Advanced Liver Cancer

Start date: May 20, 2022
Phase:
Study type: Observational

To observe and explore the effect of anti-angiogenesis combined with PD-1/PD-L1 therapy in the real world on the survival prognosis of patients with advanced liver cancer, and to summarize the treatment experience of a wide range of people.

NCT ID: NCT05375604 Recruiting - Clinical trials for Advanced Hepatocellular Carcinoma (HCC)

A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From Primary Gastric Cancer and Colorectal Cancer (CRC)

Start date: May 16, 2022
Phase: Phase 1
Study type: Interventional

This is a first-in-human, Phase 1 open-label, multicenter, dose escalation, safety, pharmacodynamic, and PK study of exoASO-STAT6 (CDK-004) in patients with advanced Hepatocellular Carcinoma (HCC) and patients with liver metastases from primary gastric cancer and colorectal cancer (CRC).

NCT ID: NCT05371873 Enrolling by invitation - Clinical trials for Hepatocellular Carcinoma

A Study of Chromosomal Abnormalities as a Predictor of Staging and Prognosis in Patients With Liver Cancer

Start date: March 1, 2021
Phase:
Study type: Observational

Liver cancer is one of the most common malignant tumors worldwide with high morbidity and mortality, and hepatocellular carcinoma (HCC) is the main histological subtype. So far, liver resection is the most effective treatment but the postoperative recurrence rate is high at five years, and the prognosis is difficult to estimate. Microvascular invasion (MVI) and postoperative minimal residual disease (MRD) are crucial prognostic factors for patients undergoing hepatectomy. Although many laboratory and imaging methods have been established to estimate the recurrence risk, their stability and accuracy are still not high. To date, no unified conclusion is achieved. It's eagerly to screen out a batch of individualized staging and prognosis-related biological indicators for early warning and prediction of prognosis, having good stability and high precision. Circulating cell-free DNA (cfDNA) molecular detection technology is an emerging detection technology of tumor gene profiling in recent years, which can be used to predict and monitor tumor recurrence. In this study, by detecting genomic chromosomal abnormalities in plasma and tumor tissues of patients before and after surgery, the investigators hope to construct a preoperative MVI prediction model and a postoperative MRD monitoring model, so as to provide reference for the precise treatment of HCC.

NCT ID: NCT05370001 Not yet recruiting - Liver Tumor Clinical Trials

Endotracheal Tube Size Effect on the Carbon Dioxide Washout During Jet Ventilation

Start date: May 2022
Phase: N/A
Study type: Interventional

High Frequency Jet Ventilation (HFJV) can be used in liver tumour ablation to minimise breathing related movements. The jet cannula is placed freely inside an endotracheal tube (ETT) and the outflow of air is passive, moving out in the interspace between the jet cannula and the inner walls of the ETT. This study aims to investigate whether the tube size can influence the washout of carbon dioxide using two different sizes of ETT's.

NCT ID: NCT05369650 Recruiting - Liver Cancer Clinical Trials

To Explore the Safety and Efficacy of Intravenous Infusion of Different Doses of Lidocaine in Patients

Start date: July 27, 2019
Phase: N/A
Study type: Interventional

All patients who met the inclusion criteria were randomly divided into four groups, 30 cases in each group, which were lidocaine group 1, lidocaine group 1.5, lidocaine group 2, and the placebo group In lidocaine group 1, lidocaine group 1.5, and lidocaine group 2, 1% lidocaine 1.5 mg/kg was intravenously infused with a micropump after anesthesia induction, and the infusion was completed within 10 minutes according to the ideal body weight, and then continued for 1% lidocaine was infused at 1 mg/kg.h, 1.5 mg/kg.h and 2 mg/kg.h respectively until the end of the operation. In the placebo group, the same volume of normal saline was used instead.

NCT ID: NCT05361538 Not yet recruiting - Clinical trials for Hepatocellular Cancer

Study of Microwave Thermosphere Ablation and Traditional Microwave Ablation in Single Hepatocellular Carcinoma ≤5cm

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

Comparison of the progression-free survival, overall survival, local progression rates, complete ablation rates and the complications rate of MTA and traditional MWA in the treatment of single hepatocellular carcinoma with a diameter of ≤5cm.

NCT ID: NCT05361252 Completed - Fluid Management Clinical Trials

Stroke Volume Variation-guided Fluid Infusion in Major Liver Tumour Resection

Start date: February 1, 2017
Phase: N/A
Study type: Interventional

Studies have demonstrated that the rate of change in stroke volume variation (SVV) can be used to determine the volume of body fluids during major abdominal surgery. Anaesthesiologists can use SVV as a guide for the appropriate administration of intraoperative fluids to improve postoperative prognoses. Liver surgery is a major abdominal operation, and the amount of blood lost is typically higher than that during other general abdominal surgeries. Blood loss is positively correlated with the intraoperative fluid infusion volume, and greater blood loss is associated with more postoperative complications. Additionally, comorbid liver disease or cirrhosis can increase the complexity of liver tumour resection, causing difficulty in assessing intravascular volume and determining the appropriate intraoperative infusion volume.

NCT ID: NCT05360420 Not yet recruiting - Liver Cancer Clinical Trials

Diagnosis of Nodules ≤2 cm Based on US and CEUS Compared With Current Clinical Procedure

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

Due to different etiologies, diagnosis and treatment of HCC in China is different from that in Western countries.US is an important screening method for HCC in patients with liver cirrhosis. CEUS, as an enhanced imaging method based on US, has the advantages of convenience, non-radiation, low cost, short examination time, and the diagnostic performance of HCC is comparable to that of CECT, CEMRI, and hepatobiliary-specific MRI. It is of great significance to consider the cost-effectiveness of each examination based on the principle of cost minimization. Therefore, we propose immediate CEUS examination for suspicious lesions ≤2 cm screened by US, and determine the diagnostic process of further diagnostic methods based on the CEUS results. The aim of this study is to establish a screening and diagnosis process for HCC ≤2 cm suitable for China considering time effect, economic effect and diagnostic efficiency.

NCT ID: NCT05354674 Not yet recruiting - Colorectal Cancer Clinical Trials

Multimodal Deep Learning Radiomic Nomogram for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis

Start date: June 15, 2022
Phase:
Study type: Observational

Establishment and validation of the deep learning model of bevacizumab efficacy in simultaneous RAS mutant unresectable CRLM patients

NCT ID: NCT05342350 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Surveillance and Treatment Of Primary Hepatocellular Carcinoma: An International Prospective Observational Cohort Study of High-Risk Patients for HCC Using Liquid Biopsy

STOP-HCC
Start date: April 15, 2022
Phase:
Study type: Observational [Patient Registry]

This study has two purposes. One is to conduct a phase IV biomarker validation study in which the investigators will prospectively survey a cohort of patients at risk for liver cancer using semi-annual abdominal ultrasound and GALAD Score for 5 years. The GALAD score is a serum biomarker-based panel that can aid in early detection among patients with a high risk for liver cancer. One is to establish a bio-repository of longitudinally collected bio-specimens from patients with fibrosis/cirrhosis as a reference set for future research.